Ghosh et al., 2013)
ADA: Once-Weekly Cagrilintide + Semaglutide Promising in Type 2 Diabetes FRIDAY, June 12, 2026 -- Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter 2 inhibitor (SGLT2i), and using basal insulin, according to three studies published online June 7 in The Lancet Diabetes & Endocrinology and The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans
[DOI] [PubMed] [Google Scholar] Dong Z., Liang Z., Guo M., Hu S., Shen Z., Hai X
Understanding BPC-157: A Quick Primer BPC-157 in brief: Definition: BPC-157 (Body Protection Compound-157) is a synthetic peptide, a short chain of 15 amino acids, derived from a protective protein naturally present in human gastric juice
For patients with thyroid disease specifically, the HealthRX.com Medical Team recommends: closer TSH monitoring in the first 6 months of GLP-1 therapy, discussion of the MTC boxed warning with an endocrinologist (not a reason to avoid the drug in most cases, but a reason to have the conversation), and awareness that levothyroxine absorption timing may need adjustment
In the new study, a team led by Dr
